Techulon wins $1.9M DARPA contract to develop superbug treatment

05/10/2013 | Genetic Engineering & Biotechnology News

Techulon landed a Phase II, $1.9 million contract with the U.S. Defense Advanced Research Projects Agency to further develop its therapeutic program for multidrug-resistant bacteria, or superbugs. The firm plans to use the money to take a nanotherapeutic agent toward clinical trials.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA